The Sartor laboratory has both methodological and biomedical areas of focus. Their methodological focus is bioinformatics methods and tools for the analysis of genome-wide regulatory and epigenomics data, and for assessing the biological/clinical significance of results. For instance, Dr. Sartor is a member of the Impact of Genomic Variants on Function (IGVF) NIH Consortium, for which she is developing a coupled tensor-matrix completion method to prioritize disease-specific variant-gene target pairs. The Sartor Lab also focuses on multi-omics approaches for biomarker and treatment-target discovery in disease, focusing specifically on Amyotrophic Lateral Sclerosis (ALS) and head and neck squamous cell carcinomas (HNSCC). Dr. Sartor is PI of an R01 studying downstream consequences of HPV integration in HPV-associated HNSCC, and Co-PI of a Transformative R01 linking environmental exposures with multi-omics in ALS. Being formally trained in biostatistics, Dr. Sartor uses machine learning and statistical approaches to make advances in the above areas.